Insperity

NSP · NYSE

$50.02+$0.98 (+2.00%)TodayMarket closed · Oct 20, 6:30 PM ET

Prev close $49.04

NSP analyst rating

SellConsensus of 3 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold1
Underperform2
Sell0

12-month price target · 5 analysts

Average $57.46 (+14.9% upside)

Low: $52.52
Now: $50.02
High: $64.05

Upgrades and downgrades

The latest rating actions, newest first

NSP analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Jul 22, 2026	Maintains	Hold	$35.00 → $52.00	61%
JP Morgan	May 1, 2026	Maintains	Underweight	$35.00 → $33.00	0%
Truist Securities	Nov 4, 2025	Maintains	Hold	$50.00 → $35.00	61%
JP Morgan	Nov 4, 2025	Maintains	Underweight	$51.00 → $34.00	33%

The case for and against

Updated Jan 19, 2026

Bull case

Insperity Inc. is expected to see revenue growth of 4% year-over-year, leading to projected revenues of approximately $1.62 billion, while maintaining a steady average workforce service employee base of 313,000, reflecting a 1% increase. The company’s strategic partnership with WDAY is anticipated to enhance growth potential and client retention among middle-market businesses, thereby creating significant operational efficiencies. Furthermore, Insperity's focus on providing comprehensive human resource solutions positions it favorably within a growing Professional Employer Organization (PEO) industry, catering to the increasing demand from small and midsize enterprises for outsourced HR services.

Bear case

Insperity Inc. is facing a negative outlook primarily due to weaker-than-expected hiring activity among Workforce Solutions and Employee Engagement (WSEEs), which indicates challenges in attracting new business. Additionally, the company's second-quarter results missed estimates and guidance largely due to increased healthcare benefit costs, which have significantly impacted overall profitability projections. Moreover, Insperity has issued downside guidance for the fourth quarter, reflecting continued pressure from these healthcare costs and a lowered outlook for 2025, suggesting persistent challenges ahead.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.